MeiraGTx Announces Third Quarter 2023 Financial and Operational Results
Bota-vec for the Treatment of XLRP:
- Bota-vec for the Treatment of XLRP:
Enrollment completed in second quarter 2023 in the pivotal Phase 3 LUMEOS clinical trial in collaboration with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company. - In September 2023, the IND for bota-vec for the treatment of XLRP was transferred from MeiraGTx to Janssen.
- Results from AQUAx Phase 1 open-label, dose-escalation study of gene therapy with AAV2-hAQP1 as a treatment for RIX and parotid gland hypofunction presented at ESGCT 2023 Annual Congress on October 26, 2023.
- License revenue was $5.1 million for the quarter ended September 30, 2023, compared to $4.8 million for the quarter ended September 30, 2022.